Terms: = Uterine cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Staging
31 results:
1. Comprehensive analysis of clinical prognosis and biological significance of CNIH4 in cervical cancer.
Wang J; Wang S; Wang J; Huang J; Lu H; Pan B; Pan H; Song Y; Deng Q; Jin X; Shi G
Cancer Med; 2023 Dec; 12(24):22381-22394. PubMed ID: 38087815
[TBL] [Abstract] [Full Text] [Related]
2. It is not the time to abandon intraoperative frozen section in endometrioid adenocarcinoma: A large-scale, multi-center, and retrospective study.
Yang X; Yin J; Fu Y; Shen Y; Zhang C; Yao S; Xu C; Xia M; Lou G; Liu J; Lin B; Wang J; Zhao W; Zhang J; Cheng W; Guo H; Guo R; Xue F; Wang X; Han L; Li X; Zhang P; Zhao J; Li W; Dou Y; Wang Z; Liu J; Li K; Chen G; Sun C; Wang B; Yang X
Cancer Med; 2023 Apr; 12(7):8897-8910. PubMed ID: 36718983
[TBL] [Abstract] [Full Text] [Related]
3. Targeted Therapies in the Treatment of uterine Serous Carcinoma.
Tymon-Rosario JR; Gorman M; Santin AD
Curr Treat Options Oncol; 2022 Dec; 23(12):1804-1817. PubMed ID: 36447064
[TBL] [Abstract] [Full Text] [Related]
4. Nodal Assessment in Endometrial Atypical Hyperplasia.
Capozzi VA; Sozzi G; Butera D; Chiantera V; Ghi T; Berretta R
Gynecol Obstet Invest; 2022; 87(3-4):226-231. PubMed ID: 35793641
[TBL] [Abstract] [Full Text] [Related]
5. Stearoyl-CoA desaturase 1 regulates malignant progression of cervical cancer cells.
Wang L; Ye G; Wang Y; Wang C
Bioengineered; 2022 May; 13(5):12941-12954. PubMed ID: 35609330
[TBL] [Abstract] [Full Text] [Related]
6. Factors associated with an increased risk of recurrence in patients diagnosed with high-grade endometrial cancer undergoing minimally invasive surgery: A study of the society of gynecologic oncology of Canada (GOC) community of practice (CoP).
Feigenberg T; Cormier B; Gotlieb WH; Jegatheeswaran K; Helpman L; Kim SR; Lau S; May T; Saab D; Plante M; Renaud MC; Samouelian V; Shamiya S; Vicus D; Wright K; Kwon JS
Gynecol Oncol; 2021 Sep; 162(3):606-612. PubMed ID: 34183164
[TBL] [Abstract] [Full Text] [Related]
7. UBE2C Drives Human Cervical cancer Progression and Is Positively Modulated by mTOR.
Chiang AJ; Li CJ; Tsui KH; Chang C; Chang YI; Chen LW; Chang TH; Sheu JJ
Biomolecules; 2020 Dec; 11(1):. PubMed ID: 33396624
[TBL] [Abstract] [Full Text] [Related]
8. A proposal for a new classification of "unfavorable risk criteria" in patients with stage I endometrial cancer.
Li R; Shinde A; Han E; Lee S; Beriwal S; Harkenrider M; Kamrava M; Chen YJ; Glaser S
Int J Gynecol Cancer; 2019 Sep; 29(7):1086-1093. PubMed ID: 31474587
[TBL] [Abstract] [Full Text] [Related]
9. Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.
Aloisi A; Casanova JM; Tseng JH; Seader KA; Nguyen NT; Alektiar KM; Makker V; Chiang S; Soslow RA; Leitao MM; Abu-Rustum NR
Gynecol Oncol; 2018 Dec; 151(3):395-400. PubMed ID: 30286945
[TBL] [Abstract] [Full Text] [Related]
10. Increased ZNF84 expression in cervical cancer.
Li P; Guo H; Zhou G; Shi H; Li Z; Guan X; Deng Z; Li S; Zhou S; Wang Y; Wang S
Arch Gynecol Obstet; 2018 Jun; 297(6):1525-1532. PubMed ID: 29610946
[TBL] [Abstract] [Full Text] [Related]
11. MicroRNA-409 inhibits the proliferative ability of cervical carcinoma cells by regulating akt.
Li B; Wu N; Zhang XJ; Wei ZL; Shang LX
Eur Rev Med Pharmacol Sci; 2018 Feb; 22(4):936-942. PubMed ID: 29509241
[TBL] [Abstract] [Full Text] [Related]
12. Long Noncoding RNA GAS5, Which Acts as a Tumor Suppressor via microRNA 21, Regulates Cisplatin Resistance Expression in Cervical cancer.
Wen Q; Liu Y; Lyu H; Xu X; Wu Q; Liu N; Yin Q; Li J; Sheng X
Int J Gynecol Cancer; 2017 Jul; 27(6):1096-1108. PubMed ID: 28472815
[TBL] [Abstract] [Full Text] [Related]
13. uterine sarcoma part III-Targeted therapy: The Taiwan Association of Gynecology (TAG) systematic review.
Yen MS; Chen JR; Wang PH; Wen KC; Chen YJ; Ng HT;
Taiwan J Obstet Gynecol; 2016 Oct; 55(5):625-634. PubMed ID: 27751406
[TBL] [Abstract] [Full Text] [Related]
14. Minimally invasive surgical management of early-stage cervical cancer: an analysis of the risk factors of surgical complications and of oncologic outcomes.
Garabedian C; Merlot B; Bresson L; Tresch E; Narducci F; Leblanc E
Int J Gynecol Cancer; 2015 May; 25(4):714-21. PubMed ID: 25647258
[TBL] [Abstract] [Full Text] [Related]
15. Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer.
Schuler KM; Rambally BS; DiFurio MJ; Sampey BP; Gehrig PA; Makowski L; Bae-Jump VL
Cancer Med; 2015 Feb; 4(2):161-73. PubMed ID: 25417601
[TBL] [Abstract] [Full Text] [Related]
16. Factors predicting nodal metastasis in endometrial cancer.
Gilani S; Anderson I; Fathallah L; Mazzara P
Arch Gynecol Obstet; 2014 Dec; 290(6):1187-93. PubMed ID: 24981050
[TBL] [Abstract] [Full Text] [Related]
17. Immunolocalization of ERK1/2 and p-akt in normal endometrium, endometrial hyperplasia, and early and advanced stage endometrioid endometrial adenocancer and their prognostic significance in malignant group.
Gungorduk K; Ertas IE; Sahbaz A; Ozvural S; Sarica Y; Ozdemir A; Sayhan S; Gokcu M; Yilmaz B; Sanci M; Inan S; Harma M; Yildirim Y
Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():147-52. PubMed ID: 24965996
[TBL] [Abstract] [Full Text] [Related]
18. Targeted therapy in uterine serous carcinoma: an aggressive variant of endometrial cancer.
Black JD; English DP; Roque DM; Santin AD
Womens Health (Lond); 2014 Jan; 10(1):45-57. PubMed ID: 24328598
[TBL] [Abstract] [Full Text] [Related]
19. Endometrial cancer: molecular and therapeutic aspects.
Tsikouras P; Bouchlariotou S; Vrachnis N; Dafopoulos A; Galazios G; Csorba R; von Tempelhoff GF
Eur J Obstet Gynecol Reprod Biol; 2013 Jul; 169(1):1-9. PubMed ID: 23433742
[TBL] [Abstract] [Full Text] [Related]
20. Should all endometrioid uterine cancer patients undergo systemic lymphadenectomy?
Wang ZQ; Wang JL; Shen DH; Li XP; Wei LH
Eur J Surg Oncol; 2013 Apr; 39(4):344-9. PubMed ID: 23333067
[TBL] [Abstract] [Full Text] [Related]
[Next]
